Cargando…

Comment on “The End of Phase 3 Clinical Trials in Biosimilars Development?”

Detalles Bibliográficos
Autores principales:	Webster, Christopher J., Woollett, Gillian R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2018
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182457/ https://www.ncbi.nlm.nih.gov/pubmed/30117118 http://dx.doi.org/10.1007/s40259-018-0297-y

Ejemplares similares

Comment on “Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU-Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development?”
por: Webster, Christopher J., et al.
Publicado: (2019)

A ‘Global Reference’ Comparator for Biosimilar Development
por: Webster, Christopher J., et al.
Publicado: (2017)

An Efficient Development Paradigm for Biosimilars
por: Webster, Christopher J., et al.
Publicado: (2019)

Authors’ Reply to Pires et al.: “Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes”
por: Cohen, Hillel P., et al.
Publicado: (2018)

Worldwide experience with biosimilar development
por: McCamish, Mark, et al.
Publicado: (2011)

Comment on “Biosimilar FSH preparations- are they identical twins or just siblings?”
por: Strowitzki, Thomas, et al.
Publicado: (2016)

Comment on “New Alternatives for Autoimmune Disease Treatments: Physicochemical and Clinical Comparability of Biosimilar Etanercept”
por: Hassett, Brian, et al.
Publicado: (2018)

Comment on: “Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes”
por: Pires, Antonio, et al.
Publicado: (2018)

Response to: Comment on “New Alternatives for Autoimmune Disease Treatments: Physicochemical and Clinical Comparability of Biosimilar Etanercept”
por: Miranda-Hernández, Mariana P., et al.
Publicado: (2018)

Response to Comments on the CAG/CCC Position Statement on Biosimilars for Inflammatory Bowel Disease
por: Moayyedi, Paul, et al.
Publicado: (2020)

Future Evolution of Biosimilar Development by Application of Current Science and Available Evidence: The Developer’s Perspective
por: Cohen, Hillel P., et al.
Publicado: (2023)

Comment on Hernandez-Vasquez et al., a bibliometric analysis of the global research on biosimilars
por: Cohen, Hillel P.
Publicado: (2018)

Comment on ‘End of the road for Essure®?’
por: Das, Sayantana, et al.
Publicado: (2018)

The Role of PD Biomarkers in Biosimilar Development – To Get the Right Answer One Must First Ask the Right Question
por: Woollett, Gillian R., et al.
Publicado: (2022)

Biosimilars: The naming puzzle
por: Gaur, Rajneesh Kumar
Publicado: (2015)

A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma
por: Shi, Yuankai, et al.
Publicado: (2020)

Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes
por: Cohen, Hillel P., et al.
Publicado: (2018)

Ophthalmic biosimilars: Lessons from India
por: Sharma, Ashish, et al.
Publicado: (2019)

Expected Impact of Biosimilars on the Pharmaceutical Companies
por: Golshani, Shiva, et al.
Publicado: (2021)

The Continuum of Comparability Extends to Biosimilarity: How Much Is Enough and What Clinical Data Are Necessary?
por: McCamish, M, et al.
Publicado: (2013)

Comment on: “Safety of Marketed Cancer Supportive Care Biosimilars in the U.S.: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database”
por: Putzke, Joerg, et al.
Publicado: (2021)

Biosimilar insulins: An unavoidable option in South-East Asia
por: Kaduskar, Prashant Ulhas
Publicado: (2016)

Comments on “Whole lung irradiation as a novel treatment for COVID-19: Interim results of an ongoing phase 2 trial in India”
por: Ghaznavi, Hamid, et al.
Publicado: (2022)

Comment On: Prospective Phase II Trials Validate the Effect of Neoadjuvant Chemotherapy on Pattern of Recurrence in Pancreatic Adenocarcinoma
por: Liu, Zhi-Peng, et al.
Publicado: (2023)

India and End of Life Discussions: A Comment on End of Life Discussion in an Academic Family Health Team in Kingston, Ontario, Canada
por: Raina, Sunil Kumar, et al.
Publicado: (2014)

Comment on “Analysis and Thoughts about the Negative Results of International Clinical Trials on Acupuncture”
por: Jackson, Leigh
Publicado: (2015)

Comment on “Economic Burden and Medical Insurance Impact of the Different Dialysis for End-Stage Renal Diseases”
por: Bayati, Mohsen
Publicado: (2019)

Serious Games Without Screens. Comment on “Involvement of End Users in the Development of Serious Games for Health Care Professions Education: Systematic Descriptive Review”
por: Cosimini, Michael Joseph, et al.
Publicado: (2022)

Author's reply for comment on “positive end-expiratory pressure valve malfunctioning detected by capnographic and airway pressure waveform”
por: Solanki, Sohan Lal, et al.
Publicado: (2015)

bDMARDs retention rate in the biosimilar era: A real-life monocentric study
por: Becciolini, Andrea, et al.
Publicado: (2021)

Response to comments on “Whole lung irradiation as a novel treatment for COVID-19: Interim results of an ongoing phase 2 trial in India”
por: Ganesan, Govindaraj, et al.
Publicado: (2022)

Comment on a new treatment strategy for end-stage hepatic alveolar echinococcosis: IVC resection without reconstruction
por: Akbulut, Sami, et al.
Publicado: (2021)

A few comments about the evaluation for small and diminutive colorectal polyps in end-stage renal disease patients
por: Lei, Tiantian, et al.
Publicado: (2022)

Comment on: “Clinical Pharmacokinetics of Atypical Antipsychotics: An Update”
por: Periclou, Antonia, et al.
Publicado: (2019)

A Case of Isotretinoin Therapy-Refractory Folliculitis Decalvans Treated Successfully with Biosimilar Adalimumab (Exemptia)
por: Shireen, Furtado, et al.
Publicado: (2018)

Randomized trial of vilazodone versus sertraline in depression: Concerns and comments
por: Praharaj, Samir Kumar
Publicado: (2021)

Comparability of Biologics: Global Principles, Evidentiary Consistency and Unrealized Reliance
por: Webster, Christopher J., et al.
Publicado: (2021)

Comments on “The Effect of Mindfulness on Quality of Life among Women with Premature Ovarian Insufficiency: A Randomized Clinical Trial”
por: Sharma, Payal, et al.
Publicado: (2021)

Comment on ‘effects of acetaminophen on risk taking’
por: Ross, Jennifer A, et al.
Publicado: (2021)

Response to the comments received on article “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et al
por: Udwadia, Zarir F., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_buul0q76ji746vqt1e9lh7cj96